There were no surprises in Lundbeck's Q3 report released on Wednesday morning. The company has more or less performed as it expected to – exceeding some targets, meeting some exactly, and narrowly missing others.
Revenue is one of the parameters where the company came in slightly under analysts' estimates. As expected, the company has suffered from patent loss for its drug Northera, but this has had a greater impact than expected, with revenue totaling DKK 4013 (USD 624.4m) compared to the predicted DKK 4074m (USD 633.9m).
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.